Join us in revolutionizing global cancer care with proven technology and compelling economics
Substantial R&D investment establishing proven technology platform with 230 MeV achieved at Daresbury Integration Site.
3 fractions/hour × 12 hours/day × 300 days/year × $3,000/fraction × 4 rooms
Massive global treatment capacity gap in a $500B+ oncology market. LiGHT's affordability and compactness address this critical access barrier.
~$85M per 4-room site vs. ~$250M–$300M for legacy systems. Approximately 30% of competitor capital costs with faster installation (12–18 months).
Clear path to clinical validation at Daresbury facility with UK certification process underway and strategic hospital partnerships.
Software-upgradeable to FLASH radiotherapy (ultra-high dose rate) without hardware modifications—protecting investment against clinical evolution.
Liora Technologies employs a strategic Joint Venture (JV) model that aligns stakeholder incentives, reduces partner risk, and ensures successful site deployment and operation.
3 fractions/hour × 12 hours/day × 300 days/year × $3,000/fraction × 4 rooms
Note: Actual revenues will vary based on payer mix, case complexity, market dynamics, and utilization rates. This example demonstrates the substantial revenue potential of a fully operational 4-room LiGHT facility.
Cancer remains one of the largest healthcare challenges globally, with increasing incidence and substantial unmet need for advanced radiation therapy.
Fewer than 100 proton therapy centers operate worldwide, with approximately 9,500 treatment rooms needed to meet current demand. High cost and complexity have been primary barriers to adoption.
By reducing capital costs by ~70% and installation time by ~50%, LiGHT can democratize access to proton therapy, enabling deployment in mid-tier hospitals, emerging markets, and underserved regions previously unable to afford legacy systems.
Science & Technology Facilities Council partnership provides world-class integration site in Daresbury, Warrington. This facility houses accelerator calibration, R&D operations, and will host first patient treatment in 2027.
Clinical partnership aimed at treating patients in Daresbury within certification framework. Collaboration ensures clinical validation and pathway to UK regulatory approval.
Re-establishing connection with Cleveland Clinic for US clinical validation and pathway to FDA clearance, positioning LiGHT for North American market entry.
Access the comprehensive overview of technology, market opportunity, business model, and financial projections.